朱丽丽，博士，副教授，博导、硕导
研究方向：
主要研究方向为化学生物学和结构药理学研究。包括基于靶标的药物筛选、药物靶标识别、与疾病有关靶标的结构、药物作用机制研究候选药物的确证与开发候选药物的确证与开发及基于结构生物学的创新药物设计。
1.药物筛选及新药发现
针对重要疾病如肿瘤、疟疾、糖尿病、自身免疫性疾病、病毒感染性疾病等，建立了数十种基于靶标（如dhodh、dpp4、jak1-3、tyk2、pd-1/pd-l1、cd47/sirp alpha、cd73、s1pr1-5、sars-cov-2 spike等)的药物筛选模型和活性评价体系，发现了一批活性化合物和先导化合物，为有效治疗相关疾病提供了新化学实体分子。
2. 药物靶标识别及机制研究
针对目前有大量的生物活性分子其作用靶点未知这一科学问题，开展了“有药找靶”的研究。如利用化学生物学方法和结构生物学方法首次阐释了大花旋覆花内酯抗氧化应激作用的作用机制和分子靶标。
3. 生物芯片研制及应用
建立基于微流控芯片的药物筛选系统如斑马鱼血栓芯片；将微流控技术与car-t细胞制备环节有机整合，在微流控芯片上实现car-t细胞制备。
简历：
2008年7月毕业于中国科学院福建物质结构研究所获博士学位
2008年8月至2011年7月在德国吕贝克大学生物化学系做博士后研究
2011年8月至今在华东理工大学药学院任副教授
800全讯白菜官方网站的联系方式：
电话：021-64253379. email：
所获荣誉：
u 2012年校首批优秀青年教师培育计划
u 2015年校优秀青年教师培育跟踪计划
u 2019年校青年英才培育计划
代表性研究成果：
(1) lijuan he; hongxia du; yi yang; zhihua guan; jinjin li; honglin li; xudong lin*; lili zhu*. a lateral-immobilization zebrafish microfluidic chip-based system for in vivo real-time evaluation of antithrombotic agents. chinese chemical letters, 2023, https://doi.org/10.1016/j.cclet.2023.109013.
(2) huan ge; caolin wang; chaoquan tian; yanyan diao; wanqi wang; xiangyu ma; jian zhang; honglin li; zhenjiang zhao; lili zhu*. efficacy of wwq-131, a highly selective jak2 inhibitor, in mouse models of myeloproliferative neoplasms. biomedicine & pharmacotherapy, 2022, 156: 113884.
(3) lili zhu#; lei shan#; junsheng zhu; li li; shiliang li; liyan wang; jiawei wang; shoude zhang; hongchang zhou; weidong zhang*; honglin li*; discovery of a natural fluorescent probe targeting the plasmodium falciparum cysteine protease falcipain-2. science china life sciences, 2020, 63: 1016-1025.
(4) yi tong; qian jiao; yuanru liu; jiankun lv; rui wang*; lili zhu*; maprotiline prevents monocrotaline-induced pulmonary arterial hypertension in rats. frontiers in pharmacology, 2018, 9: 1032.
(5) guozhen wu#; lili zhu#; xing yuan,; hao chen; rui xiong; shoude zhang; hao cheng; yunheng shen; huazhang an; tiejun li; honglin li*; weidong zhang*; britanin ameliorates cerebral ischemia-reperfusion injury by inducing the nrf2 protective pathway. antioxidants & redox signaling, 2017, 27(11): 754-768.
(6) fangshu wu; junsheng zhu; honglin li*; lili zhu*; structural analysis of recombinant human ubiquitin-conjugating enzymeubch5c. acta pharmaceutica sinica b, 2017, 7(3): 390–394.
(7) jiawei wang; yanyan diao; junsheng zhu; shiliang li; zhenjiang zhao; honglin li*; lili zhu*. biological evaluation of quinoline derivatives as inhibitors of human dihydroorotate dehydrogenase. medchemcomm, 2016, 7(5): 853-858.
(8) huan he; mengting xie; mengting zhang; haiqin zhang; huan zhu; yuxian fang; zihao shen; rui wang; zhenjiang zhao; lili zhu*; xuhong qian*; honglin li*. design, synthesis and biological evaluation of potent and selective s1pr1 agonists for the treatment of ulcerative colitis. chinese journal of chemistry, 2022, 22(40):2625-2632.
(9) fanxun zeng; tiantian qi; chunyan li; tingfang li; honglin li; shiliang li*; lili zhu*; xiaoyong xu*. synthesis, structure–activity relationship and binding mode analysis of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase. medchemcomm, 2017, 8: 1297.
(10) junsheng zhu; le han; yanyan diao; xiaoli ren; minghao xu; liuxin xu; shiliang li; qiang li; dong dong; jin huang; xiaofeng liu; zhenjiang zhao; rui wang; lili zhu*; yufang xu; xuhong qian*; honglin li*. design, synthesis, x-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase. journal of medicinal chemistry, 2015, 58(3): 1123-1139.
